Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
8 Apr 24
8-K
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
2 Nov 23
8-K
Pancreatic Cancer and Small Cell Lung Cancer Program Updates
26 Sep 23
8-K
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
9 Aug 23
8-K
AU GU ST 7 , 2 0 2 3 mCRC Program Update and Clinical Development Plan
7 Aug 23
8-K
Other Events
24 Jul 23
8-K
Other Events
20 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
S-8
Registration of securities for employees
12 Jul 22
S-3
Shelf registration
5 Apr 22
424B5
Prospectus supplement for primary offering
18 Nov 21
S-8
Registration of securities for employees
10 Jun 21
S-3ASR
Automatic shelf registration
12 Mar 21
424B5
Prospectus supplement for primary offering
30 Sep 20
424B5
Prospectus supplement for primary offering
29 Sep 20
424B3
Prospectus supplement
13 Jul 20
S-8
Registration of securities for employees
7 Jul 20
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
15 Apr 22
DEF 14A
Definitive proxy
14 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEF 14A
Definitive proxy
4 Mar 20
DEFA14A
Additional proxy soliciting materials
23 Apr 19
Other
EFFECT
Notice of effectiveness
26 Apr 22
CORRESP
Correspondence with SEC
21 Apr 22
UPLOAD
Letter from SEC
14 Apr 22
EFFECT
Notice of effectiveness
13 Jul 20
CORRESP
Correspondence with SEC
9 Jul 20
UPLOAD
Letter from SEC
2 Jul 20
EFFECT
Notice of effectiveness
3 Jun 20
UPLOAD
Letter from SEC
29 May 20
CORRESP
Correspondence with SEC
29 May 20
EFFECT
Notice of effectiveness
14 Nov 19